Lentiviral gene transfer into primary and secondary NOD/SCID repopulating cells
- PMID: 11090053
Lentiviral gene transfer into primary and secondary NOD/SCID repopulating cells
Abstract
The ability of lentiviral vectors to transfer genes into human hematopoietic stem cells was studied, using a human immunodeficiency virus 1 (HIV-1)-derived vector expressing the green fluorescence protein (GFP) downstream of the phosphoglycerate kinase (PGK) promoter and pseudotyped with the G protein of vesicular stomatitis virus (VSV). High-efficiency transduction of human cord blood CD34(+) cells was achieved after overnight incubation with vector particles. Sixteen to 28 percent of individual colony-forming units granulocyte-macrophage (CFU-GM) colonies derived from cord blood CD34(+) cells were positive by polymerase chain reaction (PCR) for the GFP gene. The transduction efficiency of SCID-repopulating cells (SRC) within the cord blood CD34(+) population was assessed by serial transplantation into nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. When 400,000 cord blood CD34(+) cells were transplanted into primary recipients, all primary and secondary recipients contained and expressed the transgene. Over 50% of CFU-GM colonies derived from the bone marrow of these primary and secondary recipients contained the vector on average as determined by PCR. Transplantation of transduced cells in limiting dilution generated GFP(+) lymphoid and myeloid progeny cells that may have arisen from a single SRC. Inverse PCR analysis was used to amplify vector-chromosomal junctional fragments in colonies derived from SRC and confirmed that the vector was integrated. These results show that lentiviral vectors can efficiently transduce very primitive human hematopoietic progenitor and stem cells. (Blood. 2000;96:3725-3733)
Similar articles
-
High levels of transgene expression following transduction of long-term NOD/SCID-repopulating human cells with a modified lentiviral vector.Stem Cells. 2001;19(3):247-59. doi: 10.1634/stemcells.19-3-247. Stem Cells. 2001. PMID: 11359950
-
Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis.Blood. 2003 Feb 15;101(4):1284-9. doi: 10.1182/blood-2002-07-2238. Epub 2002 Oct 17. Blood. 2003. PMID: 12393514
-
Transduction of human hematopoietic stem cells by lentiviral vectors pseudotyped with the RD114-TR chimeric envelope glycoprotein.Hum Gene Ther. 2007 Sep;18(9):811-20. doi: 10.1089/hum.2006.138. Hum Gene Ther. 2007. PMID: 17824830
-
Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. Nonobese diabetic/severe combined immunodeficient.Blood. 2002 Dec 15;100(13):4391-400. doi: 10.1182/blood.V100.13.4391. Blood. 2002. PMID: 12453876
-
Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives.EMBO Mol Med. 2019 Mar;11(3):e9958. doi: 10.15252/emmm.201809958. EMBO Mol Med. 2019. PMID: 30670463 Free PMC article. Review.
Cited by
-
Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy.Blood. 2009 Mar 5;113(10):2172-80. doi: 10.1182/blood-2008-08-173021. Epub 2009 Jan 13. Blood. 2009. PMID: 19141866 Free PMC article.
-
Transduction of human NOD/SCID-repopulating cells with both lymphoid and myeloid potential by foamy virus vectors.Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8295-300. doi: 10.1073/pnas.122131099. Proc Natl Acad Sci U S A. 2002. PMID: 12060773 Free PMC article.
-
Transcriptional targeting of lentiviral vectors by long terminal repeat enhancer replacement.J Virol. 2002 Apr;76(8):3996-4007. doi: 10.1128/jvi.76.8.3996-4007.2002. J Virol. 2002. PMID: 11907239 Free PMC article.
-
Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.Semin Hematol. 2013 Apr;50(2):101-30. doi: 10.1053/j.seminhematol.2013.03.025. Semin Hematol. 2013. PMID: 24014892 Free PMC article. Review.
-
Erythroid-specific human factor IX delivery from in vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B mice.Mol Ther. 2008 Oct;16(10):1745-52. doi: 10.1038/mt.2008.161. Epub 2008 Aug 5. Mol Ther. 2008. PMID: 18682698 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous